Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
12.04.2018 17:25:00

Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Obalon Therapeutics, Inc. (OBLN) and April 16 Lead Plaintiff Deadline

NEW YORK, April 12, 2018 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is notifying investors that class action lawsuits have been filed against Obalon Therapeutics, Inc. (NASDAQ: OBLN) ("Obalon" or the "Company") and other defendants, related to alleged violations of federal securities laws.  If you purchased Obalon securities between October 5, 2016 and January 23, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for additional information.

Obalon manufactures medical devices, including a medical gastric balloon for weight loss therapy.

The lawsuit alleges that the defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.  Specifically, defendants failed to disclose: (1) that the Company recognized revenue in violation of Generally Accepted Accounting principles; (2) that the Company lacked adequate internal controls over accounting and financial reporting; and (3) that, as a result of the foregoing, the Company's financial statements and defendants' statements about Obalon's business, operations, and prospects, were materially false and misleading at all relevant times.

On January 23, 2018, Obalon announced that "a purported whistleblower contacted KPMG LLP, the Company's independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company's fourth fiscal quarter of 2017."  The Company further stated that "Obalon's Audit Committee will oversee an internal investigation of these allegations."

On this news, Obalon's stock price fell $1.73 per share, or 33.3%, to close at $3.46 per share on January 23, 2018. The $3.46 closing price represented a total decline of nearly 77%, from the Initial Public Offering price of $15.00 per share.

What You Can Do

If you purchased Obalon securities between October 5, 2016 and January 23, 2018, dates inclusive, or if you have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at rswartz@scott-scott.comInvestors have until April 16, 2018, to move for lead plaintiff.

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.  The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

CONTACT:

Rhiana Swartz
Scott+Scott, Attorneys at Law, LLP
(844) 818-6980
rswartz@scott-scott.com

Cision View original content:http://www.prnewswire.com/news-releases/scottscott-attorneys-at-law-llp-reminds-investors-of-securities-class-action-against-obalon-therapeutics-inc-obln-and-april-16-lead-plaintiff-deadline-300629054.html

SOURCE Scott+Scott Attorneys at Law LLP

Nachrichten zu Obalon Therapeutics Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Obalon Therapeutics Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!